Clinical Trials Directory

Trials / Unknown

UnknownNCT02934685

IG-VMAT for Localized Prostate Cancer

A Phase III Randomized Study of Hypofractionated Image-guided Volumetric Modulated Arc Radiotherapy (IG-VMAT) Versus Conventionally Fractionated IG-VMAT in Patients With Localized Prostate Cancer

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
Beijing Hospital · Other Government
Sex
Male
Age
50 Years – 79 Years
Healthy volunteers
Not accepted

Summary

To determine if hypofractionated IG-VMAT (70 Gy in 28 fractions over 5.6 weeks) will result in disease-free survival (DFS) that is no worse than DFS following conventionally fractionated IG-VMAT (80Gy in 40 fractions over 8 weeks) in patients treated for localized prostate cancer. Analysis the local progression, disease-specific survival (DFS), freedom from biochemical recurrence (FFBR), and overall survival (OS) of two groups. Observe the incidence of GI and GU toxicity.

Conditions

Interventions

TypeNameDescription
RADIATIONhypofraction70 Gy in 28 fractions over 5.6 weeks
RADIATIONconvention80Gy in 40 fractions over 8 weeks

Timeline

Start date
2016-06-01
Primary completion
2017-02-01
Completion
2021-05-01
First posted
2016-10-17
Last updated
2016-11-18

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02934685. Inclusion in this directory is not an endorsement.

IG-VMAT for Localized Prostate Cancer (NCT02934685) · Clinical Trials Directory